<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550199</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI REFMAL 120</org_study_id>
    <secondary_id>IND 79,355</secondary_id>
    <nct_id>NCT00550199</nct_id>
  </id_info>
  <brief_title>LBH589 and Gemcitabine in the Treatment of Solid Tumors</brief_title>
  <official_title>A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a single center phase I dose escalation trial. LBH589 will be administered&#xD;
      orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days&#xD;
      1, 8, and 15 every 28 days. Dose escalation will begin at Dose Level 1. Three patients will&#xD;
      be enrolled at each dose level. If 1/3 patients experiences dose-limiting toxicity, the dose&#xD;
      level will be expanded to 6 patients. If 2/6 patients experience dose-limiting toxicity at a&#xD;
      specific dose level, then the previous dose level will be considered the recommended phase II&#xD;
      dose. Dose escalation will continue until the maximum tolerated dose is determined or until&#xD;
      all dose levels outlined in the protocol have been completed. A total of 10 patients will be&#xD;
      treated at the dose that is recommended for further phase II evaluation to further assess the&#xD;
      safety of the combination regimen. Toxicity assessments will be ongoing and disease&#xD;
      assessments will be repeated every 2 treatment cycles. Patients will be allowed to continue&#xD;
      on study until disease progression unless toxicity warrants drug discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to LBH589 toxicity.&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated doses and dose limiting toxicities of LBH589 in combination with gemcitabine when administered to patients with advanced incurable malignant solid tumors.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>LBH589 and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I dose escalation study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589, Gemcitabine</intervention_name>
    <description>Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.</description>
    <arm_group_label>LBH589 and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically documented metastatic or locally advanced, incurable malignancy for&#xD;
             which gemcitabine is clinically appropriate (e.g., non-small cell lung cancer, breast,&#xD;
             ovarian, bladder cancer and lymphoma).&#xD;
&#xD;
          2. Male or female patients aged ≥ 18 years old.&#xD;
&#xD;
          3. Maximum of 3 prior regimens in a metastatic setting allowed and may include other&#xD;
             targeted agents, immunotherapy and chemotherapy.&#xD;
&#xD;
          4. Measurable disease by RECIST criteria.&#xD;
&#xD;
          5. ECOG PS 0 or 1.&#xD;
&#xD;
          6. Laboratory values as follows:&#xD;
&#xD;
               -  ANC &gt; 1500/μL&#xD;
&#xD;
               -  Hgb &gt; 9 g/dL&#xD;
&#xD;
               -  Platelets &gt;100,000/uL&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  AST/SGOT and ALT/SGPT &lt; 2.5 x ULN or &lt; 5.0 x ULN in patients with liver&#xD;
                  metastases&#xD;
&#xD;
               -  Creatinine &lt; 2.0 mg/dL Or 24-hour Creatinine Clearance &gt; 50 ml/min&#xD;
&#xD;
               -  Albumin &gt; 3 g/dL&#xD;
&#xD;
               -  Potassium &gt; lower limit normal (LLN)&#xD;
&#xD;
               -  Phosphorous &gt; LLN&#xD;
&#xD;
               -  Calcium &gt; LLN&#xD;
&#xD;
               -  Magnesium &gt; LLN&#xD;
&#xD;
        8. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
        performed within 7 days prior to start of treatment. 9. Life expectancy &gt; 12 weeks. 10.&#xD;
        Accessible for treatment and follow-up. 11. All patients must be able to understand the&#xD;
        nature of the study and be given written informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer.&#xD;
             Patients who will need valproic acid for any medical condition during the study or&#xD;
             within 5 days prior to first LBH589 treatment&#xD;
&#xD;
          2. Impaired cardiac function including any of the following:&#xD;
&#xD;
               -  Screening ECG with a QTc &gt; 450 msec.&#xD;
&#xD;
               -  Congenital long QT syndrome.&#xD;
&#xD;
               -  History of sustained ventricular tachycardia.&#xD;
&#xD;
               -  Any history of ventricular fibrillation or torsades de pointes.&#xD;
&#xD;
               -  Bradycardia defined as heart rate &lt; 50 beats per minutes. Patients wit a&#xD;
                  pacemaker and heart rate &gt; 50 beats per minute are eligible.&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months of study entry.&#xD;
&#xD;
               -  Congestive heart failure (NY Heart Association class III or IV.&#xD;
&#xD;
               -  Right bundle branch block and left anterior hemiblock (bifasicular block).&#xD;
&#xD;
               -  Atrial fibrillation or flutter.&#xD;
&#xD;
          3. Uncontrolled hypertension (systolic blood pressure [BP] 180 or diastolic BP &gt;100mm Hg)&#xD;
             or uncontrolled cardiac arrhythmias.&#xD;
&#xD;
          4. Active CNS disease, including meningeal metastases.&#xD;
&#xD;
          5. Known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          6. Unresolved diarrhea &gt; CTCAE grade 1.&#xD;
&#xD;
          7. Chemotherapy, investigational drug therapy, major surgery &lt; 4 weeks prior to starting&#xD;
             study drug or patients that have not recovered from side effects of previous therapy.&#xD;
&#xD;
          8. Patient is &lt; 5 years free of another primary malignancy except if the other primary&#xD;
             malignancy is not currently clinically significant or requiring active intervention,&#xD;
             or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in&#xD;
             situ. Existence of any other malignant disease is not allowed.&#xD;
&#xD;
          9. Concomitant use of any anti-cancer therapy or radiation therapy other than protocol&#xD;
             required gemcitabine.&#xD;
&#xD;
         10. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)&#xD;
             not willing to use a double barrier method of contraception during the study and 3&#xD;
             months after the end of treatment. One of these methods of contraception must be a&#xD;
             barrier method. WOCBP are defined as sexually mature women who have not undergone a&#xD;
             hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive&#xD;
             months (i.e., who has had menses any time in the preceding 12 consecutive months).&#xD;
             Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 7 days of the first administration of oral LBH589.&#xD;
&#xD;
         11. Male patients whose sexual partners are WOCBP not using a double method of&#xD;
             contraception during the study and 3 months after the end of treatment. One of these&#xD;
             methods must be a condom.&#xD;
&#xD;
         12. Patients with gastrointestinal (GI) tract disease, causing the inability to take oral&#xD;
             medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation,&#xD;
             prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease&#xD;
             (e.g., Crohn's disease, ulcerative colitis).&#xD;
&#xD;
         13. Other concurrent severe, uncontrolled infection or intercurrent illness, including but&#xD;
             not limited to ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
         14. Patients with uncontrolled coagulopathy.&#xD;
&#xD;
         15. Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known&#xD;
             hypothyroidism who are stable on thyroid replacement are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Burris, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2007</study_first_posted>
  <last_update_submitted>August 15, 2013</last_update_submitted>
  <last_update_submitted_qc>August 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase I</keyword>
  <keyword>LBH589</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

